Marc Ditmarsch
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.
Journal: Nature medicine
Published: April 17, 2026
Obicetrapib safety analysis: Pooled phase 3 clinical trial experience.
Journal: American journal of preventive cardiology
Published: February 28, 2026
Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.
Journal: American journal of preventive cardiology
Published: February 20, 2026
Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?
Journal: American heart journal plus : cardiology research and practice
Published: January 21, 2026
The emerging role of CETP inhibition in the prevention of Alzheimer's disease.
Journal: American journal of preventive cardiology
Published: January 09, 2026
Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.
Journal: Cardiovascular diabetology
Published: December 19, 2025
Efficacy of Obicetrapib Across the Spectrum of Background Lipid-Lowering Therapies: Pooled Analyses of the BROADWAY and BROOKLYN Randomized Trials.
Journal: European journal of preventive cardiology
Published: November 18, 2025
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.
Journal: European heart journal
Published: September 29, 2025
Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background.
Journal: Journal of lipid research
Published: September 23, 2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease.
Journal: The journal of prevention of Alzheimer's disease
Published: August 19, 2025
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.
Journal: Journal of the American College of Cardiology
Published: June 30, 2025
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics.
Journal: American heart journal
Published: June 12, 2025
Last Updated: 09/26/2026